国产抗血管生成药物恩度单药维持治疗晚期结直肠癌综合疗效评价.docVIP

国产抗血管生成药物恩度单药维持治疗晚期结直肠癌综合疗效评价 ［ ］目的探讨国产抗血管生成药物恩度 （重组人血管内皮抑制素）单药维持治疗晚期结直肠 癌的临床效果，以期提高临床诊治水平。方法选取 2010年5月?2013年5月广东省佛山市顺德区龙江医 院收治的84例晚期结直肠癌患者为研究对象，均给予 化疗，12周后将其分为两组，对照组41例，观察组 43例。对照组给予生理盐水维持，观察组给予重组人 血管内皮抑制素维持，观察两组治疗效果、不良反应 及生活质量的变化。结果疗效上，对照组缓解率为 31.71%,总有效率为68.29%；观察组缓解率为55.81%, 总有效率为86.05%，两组比较差异有统计学意义（P 0.05）。结论在晚期结直肠癌患者化疗结束后使用国 产重组人血管内皮抑制素维持治疗，可有效提高临床 疗效，明显改善患者生活质量，且应用方便，副作用 少，价格适中，社会效益和经济效益明显。 ［关键词］恩度；晚期结直肠癌；临床效果 ［ ］R735.3 ［ ］A ［ ］ 1673-7210 (2015) 05 (b) -0121-04 Evaluation on comprehensive therapeutic effect of domestic anti-angiogenesis drug Endostar alone in maintenance treatment of advanced colorectal cancer CHEN Rongbin YE Ruxing WU Chuhai LIN Rongsheng LI Huai Department of Oncology, Longjiang Hospital of Shunde District in Foshan City， Guangdong Province, Foshan 528318，China [Abstract] Objective To explore the clinical effect of domestic anti-angiogenesis drug Endostar (recombinant human endostatin) alone in maintenance treatment of advanced colorectal cancer, so as to improve the clinical level of diagnosis and treatment. Methods 84 cases of patients with advanced colorectal cancer admitted to Longjiang Hospital of Shunde District in Foshan City from May 2010 to May 2013 were chosen as research objects， all patients were given chemotherapy，after 12 weeks，they were divided into two groups， with 41 cases in control group， 43 cases in observation group. The control group was given saline to maintain, the observation group was given recombinant human endostatin to maintain, the changes of curative effect， adverse reactions and quality of life of the two groups were observed. Results About the efficacy, the remission rate of control group was 31.71%， total effective rate was 68.29%； the remission rate of observation group was 55.81%， the total effective rate was 86.05%， the differences between the two groups were statistically significant (P 0.05) . Conclusion Domestic anti-angiogenesis drug recombinant human endostatin in maintenance treatment of advanced